Bayer signs license agreement for Cedilla's cyclinE1/CDK2 complex inhibitors
June 2, 2023
Bayer AG and Cedilla Therapeutics Inc. have entered into an exclusive license agreement to develop and commercialize Cedilla Therapeutics' cyclinE1/cyclin dependent kinase 2 (CDK2) complex inhibitors, which selectively address oncogenic drivers.